Virtual Library
Start Your Search
S.M. Kopeika
Author of
-
+
P1.07 - Poster Session with Presenters Present (ID 459)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: SCLC/Neuroendocrine Tumors
- Presentations: 1
- Moderators:
- Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P1.07-022 - The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer (ID 3870)
14:30 - 14:30 | Author(s): S.M. Kopeika
- Abstract
Background:
Small cell lung cancer (SCLC) as the most aggressive tumor deserves a special attention. The aim of this research was to define the place of surgery of patients with SCLC in order to improve the results of treatment.
Methods:
Clinical material for research consists of 46 patients in stage IA-IIIA with SCLC, which were radically operated in Ugra (region Russia) between 1999 and 2013. Among patients predominate males 38 (82,6%), versus females – eight (17,4%).
Results:
All patients underwent radical operations R0. All resection types were included (pneumonectomy, bilobectomy, and lobectomy). By 32 patients (69,6%) systematic nodal dissection (SND) was carried out, by 5 (10,9%) - mediastinal lymph node sampling (MLS) and by 9 patients mediastinal node dissection was not carried out. By SCLC combination treatment was used more often – 32 (69,6%). By that only in 8 cases additional adjuvant of thoracic radiotherapy was used. In 14 cases only surgical resection was used (30,4%). 5-year overall survival (OS) rate was 47,1%. Median survival rate was 58 months. Five-year OS rate by surgery combined with adjuvant chemotherapy was 52,1%, as compared to only surgical treatment – 35,6%. At I stage satisfactory results were achieved: 5-year OS rate was 69% (р<0,05), – that corresponds with results of treatment of patients with non-small cell lung cancer with similar stage of process. Median survival rate was not achieved. At II stage 5-year OS rate was 31%. Median survival rate was 46 months. At III stage unsatisfactory results were obtained. 5-year OS rate was 21%. Median survival rate was only 11 months.
Conclusion:
SCLC at I and II stages is the indication to radical treatment, mandatory including surgical resection with SND and adjuvant chemotherapy. The main method of treatment at III stage is chemotherapy or chemoradiotherapy.
